Why Starpharma (ASX:SPL) Is on Investors’ Radar After FY2026 Revenue Growth

Sonal Goyal

15 September 2026 03:07 AM AEST

Why Starpharma (ASX:SPL) Is on Investors’ Radar After FY2026 Revenue Growth

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Starpharma (ASX:SPL) is a biotechnology company focused on developing dendrimer-based technologies for pharmaceutical and healthcare applications. The company reported higher FY2026 Revenue and a reduced loss, while continuing to progress research programs, partnerships and commercial activities.

Latest Development

Starpharma released its FY2026 annual results in August 2026, providing an update on financial performance and operational activities.

During the period, the company also completed a Capital raising to support its ongoing Research and Development programs and Business activities.

Company Overview

Starpharma develops pharmaceutical and healthcare technologies based on its proprietary dendrimer platform.

The company’s programs include the DEP platform, which focuses on drug delivery applications, and SPL7013-based products targeting areas including anti-infective and healthcare applications.

Starpharma’s revenue has historically been generated through licensing arrangements, partnerships and commercial product activities.

Financial and Operational Position

For FY2026, Starpharma reported revenue of AUD 12.1 million, compared with AUD 4.9 million in FY2025.

The company reported a net loss of AUD 7.5 million for FY2026, compared with a net loss of AUD 10.0 million in the previous year.

The result reflected increased revenue contribution while the company continued Investment across its research and development activities.

Starpharma does not currently pay a Dividend and continues to focus on advancing its technology platforms and commercial opportunities.

Research and Commercial Focus

Starpharma continues to progress development activities across its dendrimer technology platform.

The company’s future growth depends on advancing research programs, securing commercial opportunities and expanding the application of its technologies.

Licensing and Partnership arrangements remain important potential contributors to future revenue generation.

What Investors May Watch Next

Investors may monitor progress across Starpharma’s development programs, commercial partnerships and the use of funds from its capital raising.

Future updates regarding licensing agreements, product opportunities and research milestones will provide further insight into the company’s commercial progress.

Risks

Biotechnology companies face risks related to research outcomes, regulatory approvals, commercial adoption and funding requirements.

Starpharma remains dependent on successful development and commercialisation of its technologies. Revenue can vary between periods due to the timing of licensing and partnership activities.

Future capital requirements and market conditions may also influence the company’s ability to progress its programs.

Key Takeaway

Starpharma has reported improved FY2026 financial performance, with higher revenue and a narrower loss while continuing to develop its dendrimer-based healthcare technologies. The company’s future progress will depend on commercial partnerships, research outcomes and the ability to convert its platform into sustainable revenue streams.

FAQs

Q: What is the ASX ticker for Starpharma Holdings Limited?

A: Starpharma Holdings Limited trades under the ticker (ASX:SPL).

Q: Why is Starpharma Holdings Limited in focus?

A: Starpharma is in focus due to its biotechnology platform, FY2026 financial performance and ongoing commercial development activities.

Q: What should investors monitor next for Starpharma Holdings Limited?

A: Investors may monitor research progress, licensing activity, funding updates and future company announcements.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.